Analytical Data
-
基因名
gp130
-
简介
Glycoprotein 130 (gp130) is a trans-membrane protein, is the common signal-transducing receptor subunit of the interleukin-6 (IL-6) family[1]. gp130 inhibits the cell growth and migration[3], decreases the STAT3 phosphorylation induced by IL-6, and decreases IL-6-induced increase of Ki67. gp130 shows anti-tumor, anti-inflammation and anti-nociceptive activity[4][5]. gp130/IL6ST Protein, Rat (HEK293, His) is a recombinant protein with a His label that consists of 614 amino acids (M4-E618) and is produced by HEK293 cells.
- Application
-
生物活性
Immobilized Human gp130, His Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha that produces 50% of the optimal binding response is found to be approximately 4.94 ng/mL. Immobilized Human gp130, His Tag at 5 μg/mL (100 μL/well) can bind Biotinylated Human IL-6 R alpha that produces 50% of the optimal binding response is found to be approximately 4.94 ng/mL.
-
别名
Interleukin-6 receptor subunit beta; IL-6R-beta; IL-6RB; gp130; CD130
-
种属
Rat
-
表达系统
HEK293
-
标签
C-His
-
纯度
Greater than 95% as determined by reducing SDS-PAGE. as determined by SDS-PAGE.
-
蛋白编号
NP_001008725.2
-
表达区间
Q23-E618
-
氨基酸序列
QLVEPCGYIYPEFPVVQRGSNFTATCVLKEKCLQVYSVNATYIVWKTNHVAVPKEQVTVINRTASSVTFTDVVFQNVQLTCNILSFGQIEQNVYGITILSGYPPDIPTNLSCIVNEGKNMLCQWDPGRETYLETNYTLKSEWATEKFPDCRTKHGTSSCMMGYTPIYFVNIEVWVEAENALGNVSSEPINFDPVDKVKPSPPHNLSVTNSEELSSILKLAWVNSGLDSILRLKSDIQYRTKDASTWIQVPLEDTVSPRTSFTVQDLKPFTEYVFRIRSIKENGKGYWSDWSEEASGTTYEDRPSKAPSFWYKVNANHPQEYRSARLIWKTLPLSEANGKILDYEVVLTQSKSVSQTYTVNGTELIVNLTNNRYVASLAARNVVGKSPATVLTIPGSHFKASHPVVDLKAFPKDNLLWVEWTPPSKPVNKYILEWCVLSENSPCIPDWQQEDGTVNRTHLRGSLLESKCYLITVTPVFPGGPGSPESMKAYLKQAAPSKGPTVRTKKVGKNEAVLEWDHLPVDVQNGFIRNYSISYRTSVGKEMVVRVDSSHTEYTLSSLSSDTLYMVHMAAYTEEGGKDGPEFTFTTLKFAQGEIE
-
蛋白长度
Partial
-
分子量
90-100 kDa.
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
gp130 is a signal transducer that plays a crucial role in the interleukin-6 (IL-6) cytokine family signaling pathways, which are integral to various physiological processes, including immune response, hematopoiesis, and inflammation. Dysregulation of gp130 signaling has been implicated in several pathologies, including autoimmune diseases, cancers, and chronic inflammatory disorders. The study of recombinant gp130 protein enables researchers to investigate its structure-function relationships, examine the dynamics of IL-6 family cytokine signaling, and explore its potential as a therapeutic target. Additionally, gp130's ability to form high-affinity complexes with IL-6 or other cytokines leads to the activation of downstream signaling pathways such as STAT3, which further highlights its importance in cellular signal transduction. Investigations into gp130 functionality can also facilitate the development of novel biomolecular inhibitors that may effectively modulate its activity in disease contexts. Overall, advancing our understanding of gp130 through recombinant protein studies is crucial for the development of new therapeutic strategies aimed at modulating immune and inflammatory responses.
